BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials

BeyondSpring Inc.

Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.
After all closings, BeyondSpring and subsidiary will own ~14.4% of SEED (down from ~41% initially).
Proceeds advance Plinabulin to registrational studies; DUBLIN-3 showed OS benefit in NSCLC.
303 study of Plinabulin + pembrolizumab/docetaxel achieved 89.3% DCR and 8.6 mo median PFS.
302 study enrolling first-line ES-SCLC patients; Plinabulin has GEF-H1 immune activation mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.